Lauren Rusckowski Duprey
Known title: Chief Transformation OfficerCIK: 0001977746
Associated companies
this person other insiders at TAK
Transaction History
| TAK | ▼ Sell | Open Market | 34,535 | $640K | 9/14/2026 | View on chart |
| TAK | ▼ Sell | Open Market | 47,586 | $814K | 8/10/2026 | View on chart |
| TAK | ▲ Buy | Grant | 45,140 | $0 | 7/1/2026 | View on chart |
| TAK | ▲ Buy | Grant | 59,990 | $0 | 4/27/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Takeda Launches Narcolepsy Drug in Asia, Presents PID Study Data
Takeda has launched its new narcolepsy treatment, ORZEYFUL, in Japan and China, marking the first availability of this orexin agonist for patients with narcolepsy type 1. The company also presented Phase 2/3 clinical data for its investigational drug TAK-881 for primary immunodeficiency disease at a recent medical conference. These pipeline advancements represent key milestones in Takeda's therapeutic portfolio expansion.
Takeda Launches Narcolepsy Drug in Asia, Presents PID Study Data. Takeda has launched its new narcolepsy treatment, ORZEYFUL, in Japan and China, marking the first availability of this orexin agonist for patients with narcolepsy type 1. The company also presented Phase 2/3 clinical data for its investigational drug TAK-881 for primary immunodeficiency disease at a recent medical conference. These pipeline advancements represent key milestones in Takeda's therapeutic portfolio expansion.